About US
Contact us
-
FDA grants breakthrough therapy status to BMS and AbbVie's myeloma drugUS-based pharmaceutical firms Bristol-Myers Squibb (BMS) and AbbVie have received breakthrough therapy designation from the US Food and Drug Administration (FDA) for elotuzumab, an investigational hum2014/5/22
-
US FDA approves Takeda's Entyvio to treat ulcerative colitis and Crohn's diseaseThe US Food and Drug Administration (FDA) has approved Japan-based Takeda Pharmaceutical Company and its US subsidiary's new biologic therapy, Entyvio (vedolizumab), for treating adults with moderatel2014/5/22
-
Shire plans to seek FDA approval for dry eye drug in early 2015Ireland-based Shire is planning to submit a new drug application (NDA) for lifitegrast to the US Food and Drug Administration (FDA) in the first-quarter of 2015. The company is seeking FDA approval f2014/5/21
-
European Commission approves simeprevir to treat hepatitis C genotype 1 and 4 infectionThe European Commission has granted marketing authorisation to simeprevir for the treatment of adults with genotype 1 and 4 chronic hepatitis C in combination with other medicinal products. Simeprevi2014/5/21
-
Novartis fails to secure FDA approval for heart failure drug serelaxinSwiss pharmaceutical firm Novartis has failed to secure approval from the US Food and Drug Administration (FDA) for RLX030 (serelaxin), a relaxin receptor agonist, as a treatment for patients with acu2014/5/20
-
FDA grants breakthrough therapy status to BMS's lymphoma drug nivolumabThe US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Bristol-Myers Squibb's (BMS) investigational PD-1 immune checkpoint inhibitor nivolumab to treat patients wit2014/5/20
-
Actelion's PAH drug Opsumit now available in EnglandActelion Pharmaceuticals UK has launched Opsumit (macitentan), which is now available on prescription in England as a new treatment option for patients with pulmonary arterial hypertension (PAH). PAH2014/5/19
-
FDA to review Teva's sNDA for pediatric indication of QNASL nasal aerosolThe US Food and Drug Administration (FDA) will review Israel-based Teva Pharmaceuticals' supplemental new drug application (sNDA) for a lower dose QNASL nasal aerosol indicated for treatment of season2014/5/19
-
ILE Pharmaceutical Materials Co. sincerely invites you to visit CPhI, ICSE & BioPh China 2014Date: June 26th – 28thAddress: Shanghai New International Expo Center , 2014( No. 2345 Longyang Road, Pudong District, Shanghai)ILE Stand No.: E1E20 Our technical staff will be at the show site to sh2014/5/16
-
U.K. court cuts Alimta exclusivity short, threatening Lilly's European salesEli Lilly ($LLY) might have succeeded in protectingAlimtafrom generics in the U.S., but in the U.K.? Not so much. Lilly lost a patent fight with Actavis ($ACT) in English High Court, in a ruling that2014/5/16